Song Jie, Liu Ke, Chen Weiwei, Liu Bin, Yang Hong, Lv Linshuoshuo, Sun Xiaohui, Mao Yingying, Ye Ding
Department of Epidemiology, School of Public Health, Zhejiang Chinese Medical University, Hangzhou, China.
Front Nutr. 2021 Dec 22;8:782270. doi: 10.3389/fnut.2021.782270. eCollection 2021.
The association between circulating vitamin D levels and risk of vitiligo was inconsistent among observational studies, and whether these observed associations were causal remained unclear. Therefore, we aimed to evaluate the effect of vitamin D on the risk of vitiigo using meta-analysis and Mendelian randomization (MR). At the meta-analysis stage, literature search was performed in PubMed and Web of Science to identify eligible observational studies examining the association of circulating 25-hydroxyvitamin D [25(OH)D] or 25-hydroxyvitamin D [25(OH)D] levels with risk of vitiligo up to April 30, 2021. Standardized mean differences (SMDs) with 95% confidence intervals (CIs) of 25(OH)D and 25(OH)D in patients with vitiligo relative to controls were pooled. Then at the MR stage, genetic instruments for circulating 25(OH)D ( = 120,618) and 25(OH)D ( = 40,562) levels were selected from a meta-analysis of genome-wide association studies (GWAS) of European descent, and summary statistics of vitiligo were obtained from a meta-analysis of three GWASs including 4,680 cases and 39,586 controls. We used inverse-variance weighted (IVW) as main method, followed by weighted-median and likelihood-based methods. Pleiotropic and outlier variants were assessed by MR-Egger regression and MR Pleiotropy RESidual Sum and Outlier (MR-PRESSO) test. In the meta-analysis, patients with vitiligo had a lower level of circulating 25(OH)D compared with controls [SMD = -1.40; 95% confidence interval (CI): -1.91, -0.89; < 0.001], while no statistically significant difference of 25(OH)D between vitiligo cases and controls was found (SMD = -0.63; 95% CI: -1.29, 0.04; = 0.064). However, in the MR analyses, genetically predicted 25(OH)D [odds ratio (OR) = 0.93, 95% CI = 0.66-1.31, = 0.66] and 25(OH)D levels (OR = 0.95, 95% CI = 0.80-1.14, = 0.60) had null associations with risk of vitiligo using the IVW method. Sensitivity analyses using alternative MR methods and instrumental variables (IV) sets obtained consistent results, and no evidence of pleiotropy or outliers was observed. Our study provided no convincing evidence for a causal effect of 25(OH)D or 25(OH)D levels on the risk of vitiligo. Further longitudinal and experimental studies, as well as functional studies are warranted to elucidate the role of vitamin D in the development of vitiligo.
在观察性研究中,循环维生素D水平与白癜风风险之间的关联并不一致,而且这些观察到的关联是否具有因果关系仍不明确。因此,我们旨在通过荟萃分析和孟德尔随机化(MR)来评估维生素D对白癜风风险的影响。在荟萃分析阶段,我们在PubMed和Web of Science中进行文献检索,以确定截至2021年4月30日,研究循环25-羟基维生素D[25(OH)D]或1,25-二羟基维生素D[25(OH)D]水平与白癜风风险之间关联的合格观察性研究。汇总了白癜风患者相对于对照组的25(OH)D和25(OH)D的标准化均数差(SMD)及95%置信区间(CI)。然后在MR阶段,从欧洲血统全基因组关联研究(GWAS)的荟萃分析中选择循环25(OH)D(n = 120,618)和25(OH)D(n = 40,562)水平的遗传工具变量,并从三项GWAS(包括4,680例病例和39,586例对照)的荟萃分析中获得白癜风的汇总统计数据。我们以逆方差加权(IVW)作为主要方法,随后采用加权中位数法和基于似然法的方法。通过MR-Egger回归和MR多效性残差总和与异常值(MR-PRESSO)检验评估多效性和异常值变异。在荟萃分析中,与对照组相比,白癜风患者的循环25(OH)D水平较低[SMD = -1.40;95%置信区间(CI):-1.91,-0.89;P < 0.001],而白癜风病例与对照组之间的25(OH)D水平无统计学显著差异(SMD = -0.63;95% CI:-1.29,0.04;P = 0.064)。然而,在MR分析中,使用IVW方法时,基因预测的25(OH)D[比值比(OR) = 0.93,95% CI = 0.66 - 1.31,P = 0.66]和25(OH)D水平(OR = 0.95,95% CI = 0.80 - 1.14,P = 0.60)与白癜风风险无关联。使用替代MR方法和工具变量(IV)集进行的敏感性分析得出了一致的结果,且未观察到多效性或异常值的证据。我们的研究没有提供令人信服的证据表明25(OH)D或25(OH)D水平对白癜风风险有因果影响。有必要进行进一步的纵向和实验研究以及功能研究,以阐明维生素D在白癜风发病过程中的作用。